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standard, and setting a cut-off scores of 20 for the DMI-18, >8
for the HADS, >5 for the PHQ-9, and >4 for the BDI-FS to
diagnose depression. CONCLUSIONS: The Spanish validated
DMI-18 scale maintains an adequate conceptual and semantic
equivalence with the original and is easily understood by
patients. It also has shown adequate sensitivity and speciﬁcity in
the detection of affective disorders with similar results to those of
the original version (sensitivity 91.7%–95.0%, speciﬁcity
68.1%–72.4%). Its sensitivity to detect depression is compara-
tively lower than the sensitivity of the convergent measures, but
its speciﬁcity if notably better.
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BACKGROUND: Patient centered care requires physicians to
accommodate views and needs of patients, but to date there has
been little evidence as to the degree of concordance between
patients and physicians in terms of their treatment goals and its
achievement. OBJECTIVES: To identify, value and compare the
treatment goals of patients and physicians for the treatment of
schizophrenia, and to measure self reported and physician per-
formance of patients with respect to these goals. METHODS: A
mixed methods approach was taken combining qualitative and
quantitative data. First, 20 relevant treatment goals were iden-
tiﬁed through patient focus groups (n = 30) and literature. A
survey was then developed to rank the goals and to rate its
importance using 5-point Likert scales. Finally degree of
achievement was assessed. The survey was administered to both
patients (n = 105) and physicians (n = 160) by trained ﬁeld
workers. Data was analyzed using means and t-tests as appro-
priate. RESULTS: We found that the three most important goals
for patients were: reduction of anxiety (80.5), improvement of
cognitive abilities (79.25), and reduced feelings of depression
(79). Physicians rated: reduction of symptoms (82.25), increase
of self-conﬁdence (80.75), and improvement of cognitive abili-
ties (80.5) as having the highest importance. When asked to rate
the performance of patients with respect to these goals, we
found that physicians continuously judged more critical than
patients. Signiﬁcant differences were found for improvement of
cognitive abilities (p < 0.05), increase of independence (p <
0.05), decrease lack of emotion (p < 0.05), increase of overall-
satisfaction (p < 0.05), improved ability to express oneself (p <
0.05), and recreation of social contacts (p < 0.05). CONCLU-
SIONS: Results suggest that schizophrenic patients and physi-
cians value treatment goals and their achievement relative
discordant. As schizophrenic patients are capable to state their
requirements, this should be considered in treatment decisions
to improve treatment outcomes.
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OBJECTIVES: While the clinical efﬁcacy of drugs for ADHD is
widely studied in clinical trials (usually randomised controlled
trials, RCTs), patient preferences with regard to their treatments
are not well understood and therefore considered to a less
extend. Aim of this study therefore was to explore the patients
perceptions of an “ideal treatment” for ADHD. METHODS:
Examination of the state of the art as reported in the literature
was followed by a qualitative study with four focus groups
consisting of 6–8 parents of ADHD-patients each. In a subse-
quent quantitative study phase, data was collected in an online or
paper-pencil self-ﬁll-in questionnaire for parents of patients and
patient (age >14 years) themselves. It included sociodemographic
data, treatment history and actual treatment and patients pref-
erences of therapy characteristics using direct measurement (23
items on a 5-point Likert-scale) as well as a discrete-choice-
experiment (DCE, 8 pairs with 6 characteristics). RESULTS: N =
213 questionnaires were ﬁlled; most of them by the parents of
patients (79% by the mothers, 9% by the fathers). Most of the
patients were male (83%) and most of them (83%) had actual
medical treatment of ADHD. Direct measurement showed “good
emotional quality of live”, “no addiction on medication”,
“improvement of concentration capability,” and “few side
effects” in the ﬁrst places. In the DCE, alternatives with “better
social quality of life (friendships etc. possible)”, “better emo-
tional quality of life (disease not all of the time mentally
present)”, and “longer duration of medication effect” were more
likely to be chosen, giving thus similar results. CONCLUSIONS:
N = 213 questionnaires were ﬁlled; most of them by the parents
of patients (79% by the mothers, 9% by the fathers). Most of the
patients were male (83%) and most of them (83%) had actual
medical treatment of ADHD. Direct measurement showed “good
emotional quality of live”, “no addiction on medication”,
“improvement of concentration capability,” and “few side
effects” in the ﬁrst places. In the DCE, alternatives with “better
social quality of life (friendships etc. possible)”, “better emo-
tional quality of life (disease not all of the time mentally
present)”, and “longer duration of medication effect” were more
likely to be chosen, giving thus similar results.
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OBJECTIVES: Traditionally, unmet needs are assessed using
claims data, clinician-reported metrics, or patient-reported
metrics from clinical trials. We seek to use patient-reported
survey data from ﬁve European countries to quantify unmet
needs of patients with depression currently using selective sero-
tonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine
reuptake inhibitors (SNRIs). This study will highlight the beneﬁts
of patient-reported survey data. METHODS: We analyzed data
from the 2007 European National Health and Wellness Survey,
an annual, cross-sectional, patient-reported survey of adults
(aged 18+) in France, Germany, Italy, Spain, and the UK. The
sample for analysis consisted of patients with diagnosed depres-
sion currently using an SSRI or SNRI and excluded patients with
bipolar disorder. Unmet needs were deﬁned as an afﬁrmative
response to the following symptoms in the past month: bothered
by feeling down, depressed or hopeless; and bothered by having
little interest or pleasure in doing things. Survey data were pro-
jected to national populations. Chi-square was used to test for
differences across countries. RESULTS: We found 1630 SSRI and
355 SNRI users in the sample, projecting to 6.93 and 1.46
million, respectively. There were 82.5% of SSRI users and 84.3%
of SNRI users who were bothered by feeling down, depressed, or
hopeless, equating to 5.71 and 1.23 million, respectively. Simi-
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larly, 78.3% of SSRI users and 81.3% of SNRI users were both-
ered by having little interest or pleasure in doing things equating
to 5.42 and 1.19 million in the larger population, respectively.
Unmet needs signiﬁcantly (p < 0.01) varied by country among
SSRI users but not SNRI users. CONCLUSIONS: Patient-
reported survey data reﬂect patients’ disease perception and are
generalizable to the population. These data show very high
unmet needs among patients with depression using SSRIs or
SNRIs in the ﬁve European countries and illustrates the remain-
ing need for treatments which can better alleviate depression
symptoms.
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OBJECTIVES: The purpose of this research is to determine if a
24-hour telephonic hotline is associated with lower post treat-
ment relapse rates for adolescents treated for psychoactive sub-
stance use disorder (PSUD). METHODS: Subjects are 246
adolescents discharged from primary substance abuse treatment
from 2005–2006. A total of 130 were discharged before imple-
mentation of the hotline and 116 were discharged after its imple-
mentation. The survey was based on a 234-item questionnaire.
Response rate was 62%. Treatment records of adolescents com-
pleting the questionnaire were obtained so treatment outcomes
from the questionnaire could be matched to variables contained
in treatment records. A comprehensive data set was created from
these two sources. Data are analyzed using three Cox regression
models. The ﬁrst model includes all 246 subjects using, as cova-
riates, psychosocial and treatment characteristics associated with
abstinence. The effects of the hotline (not available versus avail-
able) is compared by means of a stratiﬁcation variable yielding
two separate survival functions. Model two includes those
without access to the hotline and model three includes those with
access to the hotline. RESULTS: Model one indicates a better
cumulative survival function for those with access to the hotline
(Chi-square 46.9 p = 0.085). In model two (Chi-square 53.2 p =
0.025), boys and those diagnosed with alcohol abuse/dependence
are 2.8 and 3.5 times more likely to relapse (respectively), and
those on probation, those attending support groups and those
with supportive friends, are 51.2, 82.1, and 10.7% less likely to
relapse (respectively). In model three (Chi-square 49.3 p <
0.000), gender, diagnosis of alcohol abuse/dependence, and pro-
bation status, support group attendance and peer-support were
at parity. CONCLUSIONS: The telephone hotline is associated
with lower post treatment relapse rates, may improve the odds
that boys and those with alcohol abuse/dependence remain absti-
nent, and may lessen the inﬂuence of support groups and peer-
support on abstinence.
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OBJECTIVES: To improve the breadth and depth of the clinical
assessment of depressive symptomatology, a combined interview
of the 17-item Structured Interview Guide for the Hamilton
Depression Rating Scale (SIGH-D) and the 30-item Clinician
Rated Inventory of Depressive Symptomatology (IDS-C) was
translated into 20 languages. A rigorous methodology ensured
conceptual equivalence and cultural relevance across different
languages for this clinician-rated instrument. METHODS: For
languages where no translation of the existing scales was avail-
able, the translation process was conducted by a specialist in each
target country in collaboration with the developers of the two
instruments using the following methodology: 1) two forward
translations and reconciliation; 2) one backward translation; and
3) review by the sponsor’s subsidiaries. For languages where
translations of the existing scales were available, these were
integrated into the process as appropriate. RESULTS: Two chal-
lenges emerged: 1) The integration of available translations of
both existing scales required the challenging compromise of har-
monising possible divergence of wording for identical expres-
sions in the originals. The involvement of the developers of the
two existing scales was essential for this step; 2) The translation
of the original medical terms and their abbreviations were difﬁ-
cult or impossible to retain in certain target languages and para-
phrases approved by the developers had to be used. Examples
and solutions will be given during the presentation. CONCLU-
SIONS: The 20 translations of the combined interview were
established according to a rigorous methodology and in collabo-
ration with the developers of the existing scales to ensure con-
ceptual equivalence across languages. The psychometric analysis
of the data obtained from the combined interview will be neces-
sary to conﬁrm how these compare to those of the existing scales
both in the original and across languages.
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Gerhards SAH, Goossens MEJB, Huibers MJH, de Graaf LE,
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OBJECTIVES: Understanding determinants through which
health care interventions inﬂuence health outcomes may high-
light ways in which it can be maximized. This study explores the
role of pre-treatment credibility and expectancy on the outcome
of depression treatments in primary care. METHODS: Data are
used of a randomized trial comparing 1) computerized cognitive
behavioral therapy for depression (CCBT); with 2) treatment as
usual by a general practitioner (TAU); and 3) a combination of
both. Credibility and expectancy were assessed after treatment
allocation prior to treatment, with an adjusted and translated
version of the Credibility and Expectancy Questionnaire. Mod-
erators of expectancy and credibility are explored in a backward
linear regression analysis. The contribution of credibility and
expectancy to the severity of depression (BDI-II) and the quality-
of-life (SF-6D) outcome at 12 months after baseline is explored in
a stepwise linear regression, controlling for baseline depression
severity, baseline quality-of-life, sex, and age. RESULTS: The
type of intervention and educational level contribute to the level
of pre-treatment expectancy and credibility. No signiﬁcant asso-
ciation with credibility or expectancy was found for sex, age,
partner, employment status, baseline quality-of-life, baseline
severity of depression, and the presence of previous depressive
episodes during lifetime. In the CCBT and the TAU groups,
pre-treatment expectancy was associated with the depression
severity outcome, while credibility was signiﬁcant for this
outcome in TAU and tends towards signiﬁcance in the CCBT
group. For quality-of-life, only the expectancy factor contributed
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